T-DM1

This page shows the latest T-DM1 news and features for those working in and with pharma, biotech and healthcare.

Immunotherapy and future directions in oncology

Those dendritic cells can activate cytotoxic T-cells which, after replicating, track and eradicate cancer cells. ... Kadcyla (trastuzumab emtansine, Genentech of Roche) targets HER2 receptors present in breast cancer and delivers an anti-microtubule

Latest news

EU backs Roche’s Kadcyla in breast cancer

Expectations are high for the Kadcyla, which is an antibody-drug conjugate (ADC) that combines the monoclonal antibody in Herceptin with ImmunoGen's DM1, a cytotoxic payload designed to boost its
Roche's Herceptin follow-up cleared in US

FDA approval for Kadcyla (formerly T-DM1) in breast cancer. Roche won approval in the US late last week for Kadcyla, its much-anticipated follow-up to breast cancer blockbuster Herceptin. ... The FDA has given the go-ahead to Kadcyla, formerly known as
Product updates from Japan

pylori", according to the partners. Chugai Pharmaceutical has filed for approval of trastuzumab emtansine (T-DM1) - originally developed by Roche/Genentech as a follow-up to their Herceptin (trastuzumab) blockbuster - for ... Chugai has commercialisation
Roche delivers solid sales gain in 2012

Perjeta has been tipped as a future blockbuster, as has Herceptin follow-up trastuzumab emtansine ( T-DM1), which is filed in the US and Europe and expected to be on the
Genentech cancer drug delayed

Genentech is seeking approval for trastuzumab-DM1 (T-DM1) for use in patients with advanced HER2-positive breast cancer who have previously received multiple HER2-targeted medicines and chemotherapies. ... T-DM1 links ImmunoGen's tumour-activated prodrug

More from news
Approximately 2 fully matching, plus 6 partially matching documents found.

Latest Intelligence

An eye towards the biobetter in South Korea

It was noteworthy that the Celltrion's announcement happened to coincide with Roche's clinical data presentation of its Herceptin biobetter, Trastuzumab-emtansine (T-DM1). .

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest appointments

Roche names John Reed as new head of early research

investigational medicines, such as breast cancer drug T-DM1.

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Client Services Director – Medical Education Agency – North West...: Salary TBC

Senior Account Director development role to Business Director, H...: Excellent package

Engagement Expert, Healthcare Brand Communications, London: Excellent package

Account Director, Healthcare Marketing Agency: Salary TBC

Senior Director – Healthcare PR – Global Agency: Salary TBC

Associate Director: £75, 000-90, 000

Editorial Assistant Medical Education Agency: £25, 000 - £26, 000

Business Director: Competitive Salary Offered

Senior Medical Writer: Salary TBC

Account Manager / Senior Account Manager: 35, 000-40, 000

Account Director: Competitive Salary Offered

Medical Writer: Salary TBC

Global Business Development Director – Health Education: excellent commission

Account Director – Healthcare Marketing – Berks: Salary TBC

Account Director, Medical Education: Salary TBC

PRINCIPAL MEDICAL WRITER > ETL - LONDON / NEW YORK/ HOME - ME...: Salary TBC

Home-based Senior Project Manager – Independent Med Ed: Salary TBC

Senior Account Manager: Competitive Salary Offered

Technical Manager – Developer and Commercial Excellence, Healthc...: Excellent package

Account Manager / Account Director: Competative

Engagement Specialist, Healthcare Brand Communications, London, ...: circa £50K

Account Director – Health Policy – Global Agency: Salary TBC

Senior Account Manager, Rare Diseases – Medical Communications, ...: Excellent package

Subscribe to our email news alerts

PMHub

Add my company

Ashfield

Ashfield, part of UDG Healthcare plc, is a global leader in commercialisation services for the healthcare industry. We partner with...

Latest intelligence

The UK’s new five-year pricing agreement: Pharma has agreed to capped growth again - in exchange for uptake promises...
Digital applications are transforming the market access landscape: Organisations are leveraging new technology to implement a wider range of business models and, in essence, drive market access success by working smarter, faster and with greater economy....
Escaping the spin cycle of sub-optimal launch: ...